MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

ACADIA Pharmaceuticals Company Profile (NASDAQ:ACAD)

Consensus Ratings for ACADIA Pharmaceuticals (NASDAQ:ACAD) (?)
Ratings Breakdown: 1 Hold Rating(s), 8 Buy Rating(s)
Consensus Rating:Buy (Score: 2.89)
Consensus Price Target: $47.89 (59.52% upside)

Analysts' Ratings History for ACADIA Pharmaceuticals (NASDAQ:ACAD)
Show:
DateFirmActionRatingPrice TargetActions
5/3/2016Leerink SwannDowngradeOutperform -> Market PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/17/2016Cowen and CompanyReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/1/2016AegisReiterated RatingBuy$54.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/31/2016Needham & Company LLCReiterated RatingBuy$49.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/30/2016Piper JaffrayBoost Price TargetOverweight$39.00 -> $44.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/28/2016JPMorgan Chase & Co.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/28/2016Bank of AmericaReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/28/2016HC WainwrightReiterated RatingBuy$50.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/22/2016JMP SecuritiesReiterated RatingOutperform$43.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/12/2015Jefferies GroupLower Price TargetBuy$50.00 -> $47.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/6/2015Roth CapitalReiterated RatingBuy$42.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/15/2014Morgan JosephInitiated CoverageOverweightView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 5/3/2014 forward)
            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha